Table 1.

Patient demographic information for 3 phenotypes

Baseline Demographics
	C4d+ AR (n=5)	C4d− AR (n=5)	STA (n=5)	P value
Recipient
Gender, %females	20%	40%	20%	0.71
Mean age (yr)	12.0 ± 2.2	13.3 ± 2.7	8.7 ± 2.9	0.47
Immunosuppression, %SF#	100%	100%	100%	1
Post-txp sampling (mo)	37.1 ± 10.5	12.4 ± 4.7	28.0 ± 9.9	0.17
Race*	40%, 20%, 0%, 20%, 20%	80%, 20%, 0%, 0%, 0%	20%, 20%, 20%, 20%, 20%	0.65
Cause of ESRD**	20%, 0%, 20%, 60%, 0%, 0%	0%, 40%, 20%, 20%, 20%, 0%	40%, 20%, 20%, 20%, 0%, 0%	0.47
Mean HLA match	2.0 ± 0.4	3.0 ± 0.6	3.8 ± 0.9	0.3
PRA <20%	100%	100%	100%	1
Donor
Type, %LD	80%	40%	100%	0.23
Gender, %females	40%	40%	80%	0.34
Mean age, yr	31.2 ± 5.3	37.7 ± 5.8	34.8 ± 3.4	0.65

^#SF: Steroid-free immunosuppression treatment (ref), consisting of daclizumab induction + mycophenolate mofetil + tacrolimus

^*Race: 1=Caucasian; 2= Hispanic; 3=Asian; 4=African American; 5=Other

^**ESRD= End-stage Renal Disease: ESRD categories: 1= Glomerulonephritis; 2= Polycystic Kidney Disease; 3=Dysplasia; 4=Reflux Nephropathy; 5=Obstructive Uropathy; 6=Other